Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Resectable pancreatic ductal adenocarcinoma, drawn from the whole corpus: 18 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Half of patients never complete adjuvant chemotherapy; whether giving it first helps clearly resectable tumours is unproven.
Recurrence after a complete resection and full chemotherapy remains common, and no marker reliably identifies who is cured.
Background: Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), Neoadjuvant / adjuvant / perioperative. Also on OnCo: Treatment journeys · Survivorship planner.
Circulating tumour DNA and CA 19-9 kinetics are not yet validated to guide who needs more or less treatment.
Outcomes differ sharply between high-volume and low-volume surgical centres.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 15 changes by month →When this page itself was last checked or edited.
Primary DFS endpoint not met.
Alive at 18 months: 60 percent with neoadjuvant FOLFIRINOX against 73 percent with upfront surgery (p 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
PREOPANC-1 5-year OS 20.